CD70標靶治療藥的全球市場:臨床試驗和市場機會(2025年)

Global CD70 Targeting Therapies Clinical Trials & Market Opportunity Insight 2025

出版日期: 2025年01月01日 | 出版商:

KuicK Research | 英文 150 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

針對 CD70 的藥物正迅速成為治療各種癌症和免疫相關疾病的一種有希望的策略，並且正在徹底改變治療模式。細胞表面蛋白 CD70 在調節免疫系統方面至關重要，使其成為旨在選擇性攻擊患病細胞同時保護健康組織的療法的理想標靶。精準醫療的措施在腫瘤學領域尤其重要，因為化療和放射療法等傳統治療方法往往具有嚴重的副作用且療效有限。

在臨床實踐中，針對CD70的療法在治療血液系統惡性腫瘤，特別是急性髓細胞白血病（AML）和腎細胞癌（RCC）等實體腫瘤方面顯示出巨大的潛力。急性骨髓性白血病很難透過標準治療來控制，尤其是對於不適合強化化療的患者。針對 CD70 標靶治療的臨床試驗顯示出解決此問題的前景，單株抗體和工程細胞療法為治療選擇較少的患者帶來了新的希望。目前處於臨床開發階段的最先進的 CD70 標靶療法是 Argenx 發現的 cusatuzumab，該療法目前正處於與化療聯合治療 AML 患者的 2 期試驗階段。這種聯合策略旨在透過解決抗藥性機制來提高庫沙珠單抗的療效，從而改善患者的整體治療效果。

CD70標靶治療的應用不僅限於癌症治療。這些治療方法也正在針對自體免疫疾病、病毒感染和移植物抗宿主疾病 (GvHD) 進行研究，但研究仍處於早期階段。在免疫反應失調的情況下，針對 CD70 的藥物有可能調節免疫系統並恢復正常的免疫功能。擴大治療應用將大大增加人們對該領域的興趣，因為它擴大了這些療法的潛在市場。

中國已成為全球 CD70 標靶治療領域的重要競爭對手。透過增加投資和與國際公司的合作，該國蓬勃發展的生物技術產業得到了推動，從而推動了創新療法的快速發展。中國的研究機構正在加強對臨床試驗的參與度，本土生物技術公司在 CD70 標靶療法商業化方面也取得了進展。

CD70 標靶治療市場競爭日益激烈，刺激創新，包括 Allogene Therapeutics、Seagen（輝瑞）和 CRISPR Therapeutics 在內的多家公司正在開發新型療法。這些公司正在進行全面的臨床前和臨床研究，以評估治療的安全性和有效性，從而提升 CD70 標靶治療的潛力。隨著越來越多的治療方法進入臨床試驗並產生積極成果，CD70 標靶治療的商業機會正在擴大。

本報告提供全球CD70標靶治療藥市場相關調查，提供市場概要，以及藥物趨勢，臨床試驗趨勢，各地區趨勢，及加入此市場的主要企業競爭情形等資訊。

CD70 Targeting Therapies In Clinical Trials: > 20 Therapies
CD 70 Targeting Therapies Clinical Trials Insight By Company, Country, Indication and Phase
Insight On CD70 Targeting Therapy Technology Platforms
FDA & EMA Designations Insight: Orphan, FTD, RMAT Designation
Global & Regional Market Development Insight
Combination Strategies For CD70 Targeting Therapies

CD70 targeting therapies are rapidly gaining recognition as a promising strategy for the treatment of various cancers and immune-related disorders, significantly transforming the therapeutic landscape. CD70, a cell surface protein, is crucial in regulating the immune system, making it an optimal target for therapies designed to selectively attack diseased cells while preserving healthy tissues. This movement towards precision medicine is particularly vital in oncology, where traditional treatments such as chemotherapy and radiation often lead to severe side effects and limited effectiveness.

In clinical practice, CD70 targeting therapies are demonstrating considerable potential in treating hematological malignancies, particularly acute myeloid leukemia (AML), as well as solid tumors like renal cell carcinoma (RCC). AML is particularly challenging to manage with standard therapies, especially in patients who are unsuitable for intensive chemotherapy. Clinical trials focused on CD70 targeted therapies have shown promise in addressing this issue, with monoclonal antibodies and engineered cell therapies offering new hope for patients with few treatment options. The most advanced CD70-targeting therapy currently in clinical development is Cusatuzumab, created by argenx, which is presently undergoing Phase 2 trials in conjunction with chemotherapeutic agents for AML patients. This combination strategy seeks to enhance the effectiveness of Cusatuzumab by tackling resistance mechanisms and improving overall patient outcomes.

The application of CD70 targeting therapies extends beyond cancer treatment. These therapies are also being investigated for autoimmune diseases, viral infections, and graft-versus-host disease (GvHD), although they remain in the early stages of research. In these contexts, where immune responses are dysfunctional, CD70 targeting agents hold the potential to modulate the immune system and restore normal immune function. The expansion of therapeutic applications significantly fuels interest in this sector, as it broadens the potential market for these treatments.

In commercial terms, the US stands as hub for CD70 targeting therapy research and development. A robust ecosystem comprising biotechnology companies, pharmaceutical enterprises, and research institutions has driven the advancement of these therapies. Notable institutions such as Baylor College of Medicine, the National Institutes of Health, and cancer centers like City of Hope are conducting crucial clinical trials. Furthermore, regulatory support from the US FDA, including the Fast Track Designation for Adicet Bio's ADI-270 and the Regenerative Medicine Advanced Therapy designation for Allogene Therapeutics' ALLO-316, has expedited the development and commercialization processes. This regulatory endorsement is vital in facilitating access to new treatments, positioning the US as the heart for both clinical development and market introduction.

China is emerging as a significant contender in the global CD70 targeting therapy landscape. The country's rapidly growing biotechnology sector, bolstered by increased investments and partnerships with international companies, has enabled swift advancements in innovative therapies. Chinese research institutions are increasingly involved in clinical trials, while local biotech firms are progressing towards the commercialization of CD70 targeting therapies.

The intensifying competition within the CD70 targeting therapy market is fostering innovation, with several companies, including Allogene Therapeutics, Seagen (Pfizer), and CRISPR Therapeutics, developing novel treatments. These organizations are engaged in comprehensive preclinical and clinical research to assess the safety and efficacy of their therapies, thereby enhancing the therapeutic potential of CD70 targeted interventions. As more therapies enter clinical trials and yield favorable outcomes, the commercial opportunities for CD70 targeting therapies are expanding.

In conclusion, the integration of favorable clinical results and a dynamic commercial landscape establishes CD70 targeting therapies as a crucial component of the future of precision medicine. As an increasing number of companies and research organizations dedicate resources to these therapies, their capacity to tackle a diverse array of diseases expands, indicating the prospect of both clinical and commercial achievements ahead.

1. Introduction To CD70 Targeting Therapy

1.1 CD70 Targeting Therapy Overview
1.2 The Prerequisite For CD70 Targeting Therapy
1.3 Dual Role of CD70 As Diagnostic & Prognostic Biomarker

2. CD70 Targeting Therapeutic Approaches

2.1 Monoclonal Antibody
2.2 Bispecific Antibody
2.3 Tetraspecific Antibody
2.4 CAR T Cell Therapy
2.5 Antibody Drug Conjugate
2.6 CAR-NK Therapy

3. CD70 Targeting Therapies Clinical Research & Development By Indications

3.1 Leukemia
3.2 Lymphoma
3.3 Gynecologic Cancer
3.4 Renal Cell Carcinoma
3.5 Lung Cancer
3.6 Autoimmune & Inflammatory Disease
3.7 Viral Infections

4. Global CD70 Targeting Therapies Clinical Trials Overview

4.1 By Phase
4.2 By Country
4.3 By Company
4.4 By Indication
4.5 By Priority Status
4.6 Patient Segment

5. CD70 Targeting Therapies Regulatory Designations: Fast Track & Orphan Designation

6. Global CD70 Targeting Therapies Clinical Trials Insight

6.1 Preclinical
6.2 Phase I
6.3 Phase I/II
6.4 Phase II

7. CD70 Targeting Therapies Development Platforms By Company & Technology

7.1 AlloCAR T Platform
7.2 Gamma Delta Cell Platform
7.3 Tailwind Platform
7.4 DARPin Platform
7.5 SIMPLE Antibody Platform
7.6 Potelligent Technology
7.7 Off The Shelf Allogeneic Manufacturing

8. Global CD70 Targeting Therapies Current Market Trend & Developments

8.1 Current Market Outline
8.2 Future Market Forecast

9. CD70 Targeting Therapies Market Opportunity & Clinical Trends By Region

9.1 US
9.2 China
9.3 Europe

10. Combination Strategies For CD70 Targeting Therapies

10.1 In Combination With Immunotherapy
10.2 In Combination With Epigenetic Modulators
10.3 In Combination With Targeted Therapy
10.4 In Combination With Oncolytic Virus Therapy
10.5 In Combination With Chemotherapy

11. Global CD70 Targeting Therapies Market Dynamics

11.1 Market Drivers
11.2 Market Challenges

12. Competitive Landscape

12.1 Adaptimmune
12.2 Adicet Bio
12.3 Allogene Therapeutics
12.4 Ambrx (Johnson & Johnson)
12.5 Chongqing Precision Biotech
12.6 Chinook Therapeutics (Novartis)
12.7 CRISPR Therapeutics
12.8 ImmuneOnco Biopharma
12.9 Pfizer
12.10 Poseida Therapeutics

簡介目錄圖表

List of Figures

Figure 1-1: Introduction To CD70 Protein
Figure 1-2: History & Development Of CD70 Targeting Therapies
Figure 1-3: CD70 As Diagnostic & Prognostic Marker In Cancer
Figure 2-1: Approaches For Targeting CD70
Figure 3-1: Role Of CD70 In Leukemia
Figure 3-2: Molecular Partners - MP0533
Figure 3-3: MP0533 Phase I/II (NCT05673057) Study - Initiation & Completion Year
Figure 3-4: Cusatuzumab Phase II (NCT04023526) Study - Initiation & Completion Year
Figure 3-5: Cusatuzumab Phase II (NCT06384261) Study - Initiation & Completion Year
Figure 3-6: Role Of CD70 In Leukemia
Figure 3-7: CAR.70/IL-15 NK Cell Therapy Phase II (NCT05092451) Study - Initiation & Completion Year
Figure 3-8: CB CAR-NK019 Phase I (NCT05667155) Study - Initiation & Completion Year
Figure 3-9: CD70 CAR T Therapy Early Phase I (NCT04662294) Study - Initiation & Completion Year
Figure 3-10: Lymphoma: Key Market Players Conducting CD70 Clinical Research
Figure 3-11: Role Of CD70 In Gynecologic Cancers
Figure 3-12: CD70 CAR-T Therapy Phase I (NCT06010875) Study - Initiation & Completion Year
Figure 3-13: Anti-hCD70 CAR transduced PBL Phase I/II Study - Initiation & Completion Year
Figure 3-14: CTX131 Phase I (NCT05795595) Study - Initiation & Completion Year
Figure 3-15: Role Of CD70 In Renal Cell Carcinoma
Figure 3-16: Research By Allogene Therapeutics
Figure 3-17: TRAVERSE Phase 1 (NCT04696731) Study - Initiation & Completion Year
Figure 3-18: CTX131 Phase I/II (NCT05795595) Study - Initiation & Completion Year
Figure 3-19: CTX131 Phase I/II (NCT05795595) Study - Initiation & Completion Year
Figure 3-20: Role Of CD70 In Lung Cancer
Figure 3-21: Role Of CD70 In Autoimmune & Inflammatory Diseases
Figure 3-22: Role Of CD70 In Autoimmune & Inflammatory Diseases
Figure 4-1: Global - CD70 Targeting Therapies Clinical Trials By Phase (Numbers), 2025
Figure 4-2: Global - CD70 Targeting Therapies Clinical Trials By Country (Numbers), 2025
Figure 4-3: Global - CD70 Targeting Therapies Clinical Trials By Company (Numbers), 2025
Figure 4-4: Global - CD70 Targeting Therapies Clinical Trials By Indication (Numbers), 2025
Figure 4-5: Global - CD70 Targeting Therapies Clinical Trials By Priority Status (Numbers), 2025
Figure 4-6: Global - CD70 Targeting Therapies Clinical Trials By Patient Segment (Numbers), 2025
Figure 7-1: Allogene Therapeutics - AlloCAR T Platform
Figure 7-2: Adicet Bio - Gamma Delta Cell Platform
Figure 7-3: ADI-270 - CD70 CAR Yδ T Cell Therapy
Figure 7-4: Catamaran Bio - Tailwind Platform
Figure 7-5: Molecular Partners - DARPin Platform
Figure 7-6: Nkarta - CAR-NK Cells
Figure 7-7: Nkarta - Proprietary CAR-NK Cells Manufacturing Process
Figure 8-1: CD70 Targeting Therapy Current Market - Guiding Factors
Figure 8-2: Key Players In CD70 Market
Figure 8-3: CD70 Targeting Therapy Market Future - Influencing Factors
Figure 10-1: Combinations Of CD70 Therapy With Other Therapies
Figure 11-1: Global CD70 Targeting Therapy Market - Drivers
Figure 11-2: Global CD70 Targeting Therapy Market - Challenges